CD8A and glioblastoma: Furthermore, we showed that αTIGIT/αPD1 dual treatment increased the numbers of CD8+ TILs and enhanced their lytic function in GBM, supporting previous findings that this treatment can enhances IFN-γ expression in glioma-infiltrating T cells (34).